DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Duchenne Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Duchenne Muscular Dystrophy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Duchenne Muscular Dystrophy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Duchenne Muscular Dystrophy: An Overview
Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in children. It is a genetic disorder characterized by progressive muscle degeneration and weakness and is one of nine types of muscular dystrophy.
Duchenne Muscular Dystrophy is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3–5. The disease primarily affects boys, but in rare cases, it can affect girls. Duchenne Muscular Dystrophy is inherited in an X-linked pattern because the gene that can carry a Duchenne Muscular Dystrophy-causing mutation is on the X chromosome. It is caused by mutations of the Duchenne Muscular Dystrophy gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications.
Supportive and symptomatic measures are the basis of the treatment of Duchenne Muscular Dystrophy patients at every stage of the disease and include non-drug, drug, and surgical procedures. Glucocorticoids have long been established as the standard in the therapy of Duchenne Muscular Dystrophy.
Duchenne Muscular Dystrophy Market Key Facts
-
The United States accounts for the largest market size of Duchenne Muscular Dystrophy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
-
The United States accounted for the largest market size of Duchenne Muscular Dystrophy USD 623.7 Million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
-
Among the EU5 countries, the United Kingdom had the largest market size with USD 24.3 Million in 2020, while Spain had the smallest market size of Duchenne Muscular Dystrophy with USD 13.7 Million in 2020, which is expected to rise during the forecast period 2022–2032.
-
Japan accounts for USD 22.7 Million in 2020, which is expected to rise during the forecast period 2022–2032.
-
The total prevalent population of Duchenne Muscular Dystrophy in the 7MM was found to be 30,688 in 2020.
-
In the US, approximately 16,765 prevalent cases of Duchenne Muscular Dystrophy were reported in the 2020.
-
Among the EU-5 countries in 2020, the UK had the highest prevalent population of Duchenne Muscular Dystrophy patients with 2,622 cases, followed by Germany (2,596) and France (2,101). In contrast, Spain had the lowest cases (1,478) in 2020. In the EU5, there were 5,140 and 5,568 cases of ambulatory and non-ambulatory in 2020, respectively.
-
In Japan, the diagnosed prevalence of Duchenne Muscular Dystrophy was 3,214 in 2020 which is expected to rise during the forecast period.
Duchenne Muscular Dystrophy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Duchenne Muscular Dystrophy pipeline therapies. It also thoroughly assesses the Duchenne Muscular Dystrophy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Duchenne Muscular Dystrophy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Duchenne Muscular Dystrophy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Duchenne Muscular Dystrophy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Duchenne Muscular Dystrophy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Duchenne Muscular Dystrophy Epidemiology, Segmented as –
-
Total Prevalent Population of Duchenne Muscular Dystrophy
-
Age-specific Prevalent Population of Duchenne Muscular Dystrophy
-
Ambulatory and Non-ambulatory Population of Duchenne Muscular Dystrophy
-
Mutation-specific prevalent population of Duchenne Muscular Dystrophy
-
Associated Comorbidities in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Duchenne Muscular Dystrophy drugs based on their sale and market share.
The report also covers the Duchenne Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Duchenne Muscular Dystrophy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Duchenne Muscular Dystrophy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
Duchenne Muscular Dystrophy Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Duchenne Muscular Dystrophy. Currently, Roche is leading the therapeutic market with its Duchenne Muscular Dystrophy drug candidates in the most advanced stage of clinical development.
Duchenne Muscular Dystrophy Companies Actively Working in the Therapeutics Market Include
-
Santhera Pharmaceuticals
-
Sarepta Therapeutics
-
Italfarmaco
-
Wave Life Sciences Ltd
-
FibroGen
-
EDG 5506 Edgewise Therapeutics
-
Fordadistrogene movaparvovec
-
Daiichi Sankyo
-
Sarepta Therapeutics, Inc.
-
ENCell
-
Taiho Pharmaceutical
-
Solid Biosciences
-
Capricor
-
Nippon Shinyaku
-
Hansa Biopharma
And Many Others
Emerging and Marketed Duchenne Muscular Dystrophy Therapies Covered in the Report Include:
-
Vyondys 53 (Golodirsen): Sarepta Therapeutics
-
Emflaza: PTC Therapeutics
-
Exondys 51: Sarepta Therapeutics
-
Translarna: PTC Therapeutics
-
Amondys 45: Sarepta Therapeutics
-
Viltepso: Nippon Shinyaku
-
PF-06939926: Pfizer
-
Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
-
Pizuglanstat (TAS-205): Taiho Pharmaceutical
-
Givinostat: Italfarmaco
-
Pamrevlumab: Fibrogen
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Duchenne Muscular Dystrophy Competitive Intelligence Analysis
4. Duchenne Muscular Dystrophy Market Overview at a Glance
5. Duchenne Muscular Dystrophy Disease Background and Overview
6. Duchenne Muscular Dystrophy Patient Journey
7. Duchenne Muscular Dystrophy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Duchenne Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Duchenne Muscular Dystrophy Unmet Needs
10. Key Endpoints of Duchenne Muscular Dystrophy Treatment
11. Duchenne Muscular Dystrophy Marketed Therapies
12. Duchenne Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Duchenne Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Duchenne Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Duchenne Muscular Dystrophy Companies Active in the Market
17. Duchenne Muscular Dystrophy Access and Reimbursement Overview
18. KOL Views on the Duchenne Muscular Dystrophy Market
19. Duchenne Muscular Dystrophy Market Drivers
20. Duchenne Muscular Dystrophy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
Elevate your market presence and strategy in the medical devices’ industry through our meticulous market research services, driving growth and precision in every decision @ Medical Devices Market Research
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices